NCT07602205Not yet recruiting
Efficacy and Safety of Daily Home-based Hyperthermic Baths for Reducing Epileptic Seizures in CDKL5 Deficiency Disorder: A PROBE Clinical Trial
Efficacy and Safety of Daily Home-based Hyperthermic Baths for Reducing Epileptic Seizures in CDKL5 Deficiency Disorder: A Prospective, Randomized, Parallel-Controlled, Open-Label, Blinded Endpoint (PROBE) Clinical Trial
Source: ClinicalTrials.gov · Last updated 22 May 2026
Brief summary (registry, in English)
The primary objective of this research is to study the efficacy and safety of daily, home-based hyperthermic baths for reducing epileptic seizures in CDKL5 Deficiency Disorder.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 34 (estimated)
- First submitted
- 15 May 2026
- Start date
- 1 Aug 2026
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- Xuanwu Hospital, Beijing
- Diseases
- Epilepsy
- NCT number
- NCT07602205
What you commit to
- Study type: Interventional
- Planned participants: 34
- From 1 Aug 2026 to the primary completion date, 31 Dec 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who had any history of previous brain disease (including trauma, encephalitis, etc.) that were likely to precipitate seizures; defined by MRI outcomes.
Other illness
- Participants with skin ulceration or dermatologic conditions that make bathing unsuitable.
- A history of seizures induced by thermal baths, or an increase in seizure frequency after thermal baths.
- Patients who presented any clinical condition that in the opinion of the principal investigator made the patient not suitable to participate in the survey.
Other
- Parents or guardians who, based on past experiences, determine that the child has an intolerance to thermal baths.
Who the study is looking for
- A diagnosis of CDKL5 deficiency disorder, including molecular confirmation of a pathogenic CDKL5 variant and exhibiting epileptic seizures.
- Male or female participants aged 6 months to 14 years, inclusive.
- Patients presenting with drug-resistant epilepsy that seizures were uncontrolled despite the appropriate trial of at least two antiseizure medications (ASMs).
- At least 8 motor seizures during each 4 weeks in the 8-week historical seizure records preceding screening.
- Treatment regimens of 0-4 ASMs were required to be stable for at least 4 weeks before screening and throughout the intervention. Ongoing ketogenic diets were allowed if remain unchanged during screening and treatment.
- Subjects who have undergone surgical implantation of vagus nerve stimulation (VNS) will be eligible for inclusion in the study, provided they meet all of the following criteria:
- The VNS device has been in place for at least one year prior to the screening visit;
- The stimulation parameters remain unchanged throughout the duration of the trial.
- Parents or caregivers must be able and willing to maintain an accurate and comprehensive daily electronic seizure diary throughout the duration of the study.
- Participants' legal guardians willing to provide written informed consent.
Age in the registry: 6 months to 14 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.